Document Detail

Inhaled steroids improve quality of life in patients with steady-state bronchiectasis.
MedLine Citation:
PMID:  16434174     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: The effects of inhaled steroids upon the quality of life of patients with bronchiectasis remain unknown. STUDY OBJECTIVE: To analyze the effect of inhaled fluticasone propionate (FP) for 6 months upon the clinical, functional, microbiological and outcome parameters of patients with steady-state bronchiectasis not due to cystic fibrosis, and its repercussions for patient health-related quality of life (HRQoL). DESIGN: Prospective, randomized, double-blind (for effective doses) study. PATIENTS AND INTERVENTIONS: The diagnosis of bronchiectasis was made by high-resolution computed tomography. Ninety-three patients (mean age: 68.5 [8.4]) were randomized to receive 250 microg bid, 500 microg bid or no treatment with inhaled FP for 6 months. Data were collected at baseline and at 1, 3 and 6 months after the start of treatment. HRQoL was assessed using the validated Spanish version of the St. George's Respiratory Questionnaire. RESULTS: The group administered FP 1000 microg daily showed significant improvement in dyspnea (1.03 [2.1]-1.24 [2.2] points; P = 0.01-0.04), sputum production (P = 0.001), days without cough (P = 0.02) and short-acting beta-2 agonists used (P = 0.01) from the first month of treatment, with no changes in pulmonary function, number or severity of exacerbations, or microbiological profile of the sputum. As a result, an improvement in HRQoL was seen in this group after 3 months of treatment (45.4 [14.2] vs. 40.5 [13.9]; P = 0.01). CONCLUSIONS: Inhalatory FP 500 microg bid is effective from the first month of treatment for controlling the symptoms of patients with steady-state bronchiectasis-thus ensuring a significant improvement in HRQoL.
Miguel A Martínez-García; Miguel Perpiñá-Tordera; Pilar Román-Sánchez; Juan Jose Soler-Cataluña
Related Documents :
16086914 - Phase ii study of vitamin e and pentoxifylline in patients with late side effects of pe...
18245584 - Patients can provide a valid assessment of quality of life, functional status, and gene...
16115244 - Prolonged cognitive dysfunction in survivors of critical illness.
23020684 - Class ii subdivision treatment with the herbst appliance.
24130094 - Refining perforator selection for deep inferior epigastric perforator flap: the impact ...
25281894 - Compare the efficacy of inhaled budesonide and systemic methylprednisolone on systemic ...
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2006-01-24
Journal Detail:
Title:  Respiratory medicine     Volume:  100     ISSN:  0954-6111     ISO Abbreviation:  Respir Med     Publication Date:  2006 Sep 
Date Detail:
Created Date:  2006-07-31     Completed Date:  2007-06-12     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8908438     Medline TA:  Respir Med     Country:  England    
Other Details:
Languages:  eng     Pagination:  1623-32     Citation Subset:  IM    
Pneumology Unit, Requena General Hospital, Valencia, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Inhalation
Androstadienes / administration & dosage*
Bronchiectasis / drug therapy*
Bronchodilator Agents / administration & dosage*
Cough / drug therapy
Double-Blind Method
Dyspnea / drug therapy
Forced Expiratory Volume
Prospective Studies
Quality of Life
Respiratory Sounds
Vital Capacity
Reg. No./Substance:
0/Androstadienes; 0/Bronchodilator Agents; 90566-53-3/fluticasone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Bullous dermatosis associated with gemcitabine therapy for non-small-cell lung carcinoma.
Next Document:  Utilization of pulverized fuel ash in Malta.